Author Topic: "Feast or famine in MS therapeutics": Amiloride, fluoxetine, riluzole fail to work for SPMS  (Read 45 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9843
  • MS diagnosed 1980
  • Location: Pacific Northwest

This comment in The Lancet Neurology (January 22, 2020) is referring to an article in the same issue. Some researchers tried out 3 drugs aimed at the inactive form of SPMS (the type that so far has not been targeted by any of the 15 MS drugs now available)--amiloride, fluoxetine, riluzole.


Quote
Despite rigorous theoretical grounding, sound experimental design, and admirable execution, MS-SMART did not achieve its primary outcome. None of the three tested drugs slowed progression of whole-brain atrophy compared with placebo.


"Feast or famine in multiple sclerosis therapeutics":

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30487-9/fulltext


Abstract of the study referred to in the comment article above--"Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial":


https://www.ncbi.nlm.nih.gov/pubmed/31981516
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20 - 3/16/24.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
98 Views
Last post June 12, 2018, 09:18:55 pm
by agate
0 Replies
147 Views
Last post November 28, 2018, 04:41:14 pm
by agate
0 Replies
106 Views
Last post July 07, 2019, 03:31:30 pm
by agate
0 Replies
66 Views
Last post October 13, 2019, 09:35:32 pm
by agate
0 Replies
62 Views
Last post January 16, 2020, 07:35:57 pm
by agate